CD47 protein levels in chronic myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at levels of a protein called CD47 in people with chronic myeloid leukemia (CML). CD47 is sometimes called the 'do not eat me' signal because it may help cancer cells hide from the immune system. Understanding this could lead to better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with chronic myeloid leukemia (CML)
- You do not have other blood cancers like ALL, CLL, or plasma cell myeloma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at two markers on blood cells (called CD38 and CD56) in people with chronic myeloid leukemia (CML). It may help doctors understand the disease better.
This study uses a very sensitive blood test (digital PCR) to look for specific genetic mutations (changes) in the BCR::ABL1 gene in people with CML. The goal is to understand why some treatments stop working, which can help doctors choose the next best medication for you.
This study looks at how chronic myeloid leukemia (CML) affects your daily life and how care is organized in Lombardy hospitals. Researchers want to learn from your experiences to improve care for everyone with CML.
This trial is a real-life study that collects information from people living with chronic myeloid leukemia (CML). It may help doctors understand how CML treatments are used in practice and how well they work over time.
This research study examines blood cells from patients with chronic myelomonocytic leukemia (CMML), a rare blood cancer, to better understand how the disease develops and progresses. By studying your blood cells, researchers hope to learn more about what causes CMML and how to treat it better.
This study looks at a protein called CD81 in blood samples from people with myeloid leukemia. It aims to understand if CD81 levels can help predict how the disease may progress, which could guide future treatment decisions.
Hear when a new Chronic Myeloid Leukemia (CML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.